

Haematologica  
HAEMATOL/2018/204958  
Version 3

Targeting BCL2 with venetoclax is a promising therapeutic strategy for  
"double-protein-expression" lymphoma with MYC and BCL2  
rearrangements

Akiko Uchida, Yasushi Isobe, Junko Asano, Yu Uemura, Masahiro  
Hoshikawa, Masayuki Takagi, and Ikuo Miura

Disclosures: IM is a consultant for SRL, Inc. No potential conflicts of interest were disclosed by the other authors.

Contributions: AU, YI, JA, YU and MH performed the experiments. YI designed experiments. UA and YI analyzed and interpreted the data. MT and IM supervised the overall project. UA, YI and MI wrote the paper, and all authors reviewed and edit the paper.